GOV Stock Overview
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Insulet Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$154.85 |
| 52 Week High | US$304.90 |
| 52 Week Low | US$119.30 |
| Beta | 1 |
| 1 Month Change | 2.79% |
| 3 Month Change | -17.57% |
| 1 Year Change | -46.21% |
| 3 Year Change | -37.33% |
| 5 Year Change | 101.71% |
| Change since IPO | 1,252.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| GOV | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -5.2% | -5.0% | -2.0% |
| 1Y | -46.2% | -13.6% | -0.3% |
Return vs Industry: GOV underperformed the German Medical Equipment industry which returned -13.6% over the past year.
Return vs Market: GOV underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| GOV volatility | |
|---|---|
| GOV Average Weekly Movement | 5.3% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GOV has not had significant price volatility in the past 3 months.
Volatility Over Time: GOV's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 3,000 | Jim Hollingshead | www.insulet.com |
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company’s Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally.
Insulet Corporation Fundamentals Summary
| GOV fundamental statistics | |
|---|---|
| Market cap | €10.93b |
| Earnings (TTM) | €193.67m |
| Revenue (TTM) | €1.59b |
55.8x
P/E Ratio6.8x
P/S RatioIs GOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GOV income statement (TTM) | |
|---|---|
| Revenue | US$1.70b |
| Cost of Revenue | US$548.70m |
| Gross Profit | US$1.15b |
| Other Expenses | US$942.10m |
| Earnings | US$206.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | 2.95 |
| Gross Margin | 67.67% |
| Net Profit Margin | 12.16% |
| Debt/Equity Ratio | 193.2% |
How did GOV perform over the long term?
See historical performance and comparison